Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Short summary

Tralokinumab monotherapy, a monoclonal antibody targeting IL-13, significantly improved moderate-to-severe atopic dermatitis (AD) symptoms compared to placebo in two Phase III trials (ECZTRA 1 & 2). At 16 weeks, 15.8%-22.2% of patients on tralokinumab achieved an IGA score of 0/1 versus 7.1%-10.9% on placebo, and 25.0%-33.2% achieved EASI 75 versus 12.7%-11.4% on placebo.

AI-generated from the title and abstract; the full text is not read.